OncoSil Medical Limited provided a progress update on its Global Pancreatic Cancer Clinical Study Programme. Key highlights: 20th patient successfully implanted with the OncoSilTM device on January 9, 2018 at Addenbrookes Hospital, Cambridge UK; 31 patients now enrolled into the Global Pancreatic Cancer clinical study programme. OncoSil will also continue to recruit subjects beyond the initial 20 subject target to gather additional valuable clinical experience and to account for potential subject losses due to factors such as withdrawal on clinical grounds prior to implantation or protocol ineligibility.